Eli Lilly Stock Downgraded on Inflated Obesity Drug Market

Core Viewpoint - Eli Lilly's stock has experienced a decline following a downgrade by HSBC, which cited an "inflated market" for obesity drugs and deemed the stock appropriately priced [1] Group 1: Stock Performance - Eli Lilly's stock is currently trading at $967.06, down 2.2% after the downgrade [1] - The stock has a year-to-date deficit of 9.8%, but has gained over 17% in the last 12 months [3] - The 12-month consensus target price for Eli Lilly is $1,201.43, representing a 21.5% premium to current levels [2] Group 2: Analyst Ratings - A majority of analysts remain bullish on Eli Lilly, with 26 out of 30 firms rating it "buy" or better [2] - The recent downgrade by HSBC is notable given the overall positive sentiment from other analysts [1][2] Group 3: Options Market Sentiment - Options traders are leaning bearish, as indicated by a 10-day put/call volume ratio of 1.16, which is higher than 98% of annual readings [4] - The Schaeffer's put/call open interest ratio (SOIR) of 1.60 also ranks higher than all other readings from the past year, suggesting bearish sentiment [4] Group 4: Volatility Expectations - Options for Eli Lilly are currently considered affordable, with a Schaeffer's Volatility Index (SVI) of 37%, which ranks higher than 25% of all other readings from the past year [5] - This indicates that near-term option traders are pricing in relatively low volatility expectations [5]